Celiac
69 programs · 66 companies
Programs
69
Companies
66
Trials
58
MOAs
38
CGRPantWEE1iCD47iPI3KiBETiAnti-TauHPK1iEGFRiAnti-AβPCSK9i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Phase 1/2 | CD38 | ||
| JNJ-8637 | NDA/BLA | CD20 | ||
| Nirarelsin | Phase 2 | PRMT5 | ||
| NVS-5126 | Phase 3 | SHP2 | ||
| BII-1564 | Phase 2 | PSMA | ||
| Sovarasimod | Phase 1/2 | WEE1 | ||
| Semasacituzumab | Phase 3 | Nectin-4 | ||
| Bemaderotide | Phase 3 | BCL-2 | ||
| Voxamavacamten | Approved | BET | ||
| PRA-419 | Approved | Cl18.2 | ||
| TNG-8610 | NDA/BLA | GIP-R | ||
| CRB-3801 | Preclinical | Cl18.2 | ||
| Polalucimab | Phase 1/2 | KRASG12C | ||
| CSL-5840 | Phase 3 | GPRC5D | ||
| Tezesacituzumab | NDA/BLA | IL-23 | ||
| 644-5754 | Phase 3 | CDK4/6 | ||
| Polasotorasib | NDA/BLA | FXIa | ||
| TLX-9196 | Phase 1/2 | SHP2 | ||
| SAM-IIT-139 | Phase 3 | IL-23 | ||
| CER-4594 | Phase 3 | TROP-2 | ||
| XTA-2008 | Preclinical | TYK2 | ||
| AFF-3518 | Phase 1 | HER2 | ||
| CRG-4097 | Phase 3 | TIGIT | ||
| LRM-3193 | Phase 2 | Tau | ||
| Mirisotorasib | Phase 1/2 | PRMT5 | ||
| Suraosocimab | Phase 1/2 | FLT3 | ||
| ARA-160 | Phase 1 | WRN | ||
| Sotovorutinib | Phase 2/3 | AuroraA | ||
| APM-4255 | NDA/BLA | CD123 | ||
| Capitinib | Phase 1 | C5 | ||
| Pemifotisoran | Phase 1/2 | CDK4/6 | ||
| Daraglumide | Preclinical | PD-1 | ||
| MIR-6154 | Phase 2 | WEE1 | ||
| HAR-9296 | Phase 1 | CD19 | ||
| ENC-8622 | Phase 3 | Tau | ||
| Sovafotisoran | Phase 1 | KIF18A | ||
| AVA-8598 | Phase 2/3 | CD38 | ||
| Sovaratamab | Phase 2/3 | FLT3 | ||
| TNG-3308 | Preclinical | CDK4/6 | ||
| 488-733 | Phase 1/2 | KRASG12C | ||
| 458-3114 | Phase 1/2 | WRN | ||
| Mirinesiran | Phase 2 | FcRn | ||
| LPC-7933 | Phase 3 | IL-17A | ||
| BIO-2612 | Phase 1 | SMN2 | ||
| Rimarapivir | Phase 3 | PSMA | ||
| Mavusertib | Approved | Tau | ||
| Capibrutinib | NDA/BLA | PCSK9 | ||
| Rilusertib | Phase 3 | HER2 | ||
| RCE-4101 | Phase 1/2 | FXIa | ||
| TRI-2500 | Phase 1/2 | AHR | ||
| Pexatinib | Phase 3 | EGFR | ||
| Sovasacituzumab | Phase 2/3 | BET | ||
| Polainavolisib | Preclinical | CFTR | ||
| ORY-4744 | Phase 2/3 | PD-L1 | ||
| NTC-6338 | Approved | FXIa | ||
| SYN-6765 | Approved | PD-L1 | ||
| MVI-4741 | Phase 2 | SHP2 | ||
| 028-9914 | NDA/BLA | CGRP | ||
| Ivoinavolisib | Phase 2/3 | CFTR | ||
| VIN-3660 | Phase 2 | BTK | ||
| Kemalucimab | Phase 2/3 | CGRP | ||
| INS-IIT-594 | Approved | GPRC5D | ||
| RIK-IIT-812 | Phase 2 | USP1 | ||
| FUD-IIT-297 | Preclinical | EZH2 | ||
| 002-6973 | Approved | MET | ||
| Elrasacituzumab | NDA/BLA | TNFα | ||
| EWT-919 | Preclinical | AuroraA | ||
| VEE-9538 | Phase 1 | HER2 | ||
| DEF-8311 | Phase 1/2 | KRASG12C |
Trials (58)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05275202 | Terafutibatinib | Phase 1/2 | Recruiting |
| NCT06729102 | JNJ-8637 | NDA/BLA | Recruiting |
| NCT06662471 | Nirarelsin | Phase 2 | Recruiting |
| NCT07984809 | NVS-5126 | Phase 3 | Recruiting |
| NCT03122159 | BII-1564 | Phase 2 | Active |
| NCT04001486 | Sovarasimod | Phase 1/2 | Recruiting |
| NCT07464413 | Semasacituzumab | Phase 3 | Not yet recr... |
| NCT03647959 | Semasacituzumab | Phase 3 | Completed |
| NCT05861155 | Voxamavacamten | Approved | Terminated |
| NCT05426881 | CRB-3801 | Preclinical | Not yet recr... |
| NCT04425160 | CSL-5840 | Phase 3 | Terminated |
| NCT08715926 | 644-5754 | Phase 3 | Recruiting |
| NCT07417928 | SAM-IIT-139 | Phase 3 | Terminated |
| NCT03795961 | CER-4594 | Phase 3 | Not yet recr... |
| NCT04947625 | CER-4594 | Phase 3 | Completed |
| NCT05248365 | XTA-2008 | Preclinical | Recruiting |
| NCT05111904 | Mirisotorasib | Phase 1/2 | Recruiting |
| NCT04510079 | Suraosocimab | Phase 1/2 | Not yet recr... |
| NCT06972301 | ARA-160 | Phase 1 | Recruiting |
| NCT07685406 | Sotovorutinib | Phase 2/3 | Recruiting |